Story thread · 2 reports / 2 sources
Bristol Myers' partner Biokin says bispecific ADC clears fourth cancer trial in China
endpts.com · 3h · first report
How the coverage leans
Across 2 sources · syndicated copies counted once
Chinese biotech Biokin said its EGFRxHER3 bispecific antibody-drug conjugate passed a late-stage China trial in a genetically-defined form of lung cancer, buoying optimism for a similar global study led by its partner Bristol Myers Squibb. ...
The coverage
- Why Novartis, Lilly, and Bristol Myers Are Eyeing This Clinical-Stage Cancer Play
finance.yahoo.com · 2h
The conversation · 0
Sign in to join the conversation.
No comments yet — start the thread.